Literature DB >> 16284303

Mechanism of action of a novel human ether-a-go-go-related gene channel activator.

Oscar Casis1, Søren-Peter Olesen, Michael C Sanguinetti.   

Abstract

1,3-Bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) is a newly discovered activator of human ether-a-go-go-related gene (hERG) K(+) channels. Here, we characterize the effects of this compound on cloned hERG channels heterologously expressed in Xenopus laevis oocytes. When assessed with 2-s depolarizations, NS1643 enhanced the magnitude of wild-type hERG current in a concentration- and voltage-dependent manner with an EC(50) of 10.4 microM at -10 mV. The fully activated current-voltage relationship revealed that the drug increased outward but not inward currents, consistent with altered inactivation gating. NS1643 shifted the voltage dependence of inactivation by +21 mV at 10 microM and +35 mV at 30 microM, but it did not alter the voltage dependence of activation of hERG channels. The effects of the drug on three inactivation-deficient hERG mutant channels (S620T, S631A, and G628C/S631C) were determined. In the absence of channel inactivation, NS1643 did not enhance hERG current magnitude. The agonist activity of NS1643 was facilitated by mutations (F656 to Val, Met, or Thr) that are known to greatly attenuate channel inhibition by hERG blockers. We conclude that NS1643 is a partial agonist of hERG channels and that the mechanism of activation is reduced channel inactivation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16284303     DOI: 10.1124/mol.105.019943

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  46 in total

Review 1.  Revealing the structural basis of action of hERG potassium channel activators and blockers.

Authors:  Matthew Perry; Michael Sanguinetti; John Mitcheson
Journal:  J Physiol       Date:  2010-07-19       Impact factor: 5.182

2.  Differential effects of Kv11.1 activators on Kv11.1a, Kv11.1b and Kv11.1a/Kv11.1b channels.

Authors:  A P Larsen; B H Bentzen; M Grunnet
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

Review 3.  hERG quality control and the long QT syndrome.

Authors:  Brian Foo; Brittany Williamson; Jason C Young; Gergely Lukacs; Alvin Shrier
Journal:  J Physiol       Date:  2016-02-09       Impact factor: 5.182

4.  Molecular determinants of human ether-à-go-go-related gene 1 (hERG1) K+ channel activation by NS1643.

Authors:  Morten Grunnet; Jennifer Abbruzzese; Frank B Sachse; Michael C Sanguinetti
Journal:  Mol Pharmacol       Date:  2010-09-27       Impact factor: 4.436

5.  Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator.

Authors:  Matthew Perry; Frank B Sachse; Michael C Sanguinetti
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-10       Impact factor: 11.205

Review 6.  Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives.

Authors:  Rashmi R Shah
Journal:  Br J Pharmacol       Date:  2009-06-25       Impact factor: 8.739

Review 7.  Translational toxicology and rescue strategies of the hERG channel dysfunction: biochemical and molecular mechanistic aspects.

Authors:  Kai-ping Zhang; Bao-feng Yang; Bao-xin Li
Journal:  Acta Pharmacol Sin       Date:  2014-11-24       Impact factor: 6.150

8.  NS1643 interacts around L529 of hERG to alter voltage sensor movement on the path to activation.

Authors:  Jiqing Guo; Yen May Cheng; James P Lees-Miller; Laura L Perissinotti; Tom W Claydon; Christina M Hull; Samrat Thouta; Daniel E Roach; Serdar Durdagi; Sergei Y Noskov; Henry J Duff
Journal:  Biophys J       Date:  2015-03-24       Impact factor: 4.033

9.  Modulation of Kv 11.1 (hERG) channels by 5-(((1H-indazol-5-yl)oxy)methyl)-N-(4-(trifluoromethoxy)phenyl)pyrimidin-2-amine (ITP-2), a novel small molecule activator.

Authors:  Harinath Sale; Samrat Roy; Jayakumar Warrier; Srinivasan Thangathirupathy; Yoganand Vadari; Shruthi K Gopal; Prasad Krishnamurthy; Manjunath Ramarao
Journal:  Br J Pharmacol       Date:  2017-06-18       Impact factor: 8.739

10.  A single amino acid difference between ether-a-go-go- related gene channel subtypes determines differential sensitivity to a small molecule activator.

Authors:  Matthew Perry; Michael C Sanguinetti
Journal:  Mol Pharmacol       Date:  2007-12-27       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.